Novartis 石明石博士 Michael Shi 演講
TKI 258 was a FGFR1 inhibitor, but the use of TKI 258 causes FGF23/bFGF increased. Melanoma trial found FGF mediated escape form anti-angiogenesis (sorxxxtinb/…) Early phase: VEGFR2 blockadge. Phase 3 trials: (a) FGFR3 expression/t94,14) trans-location in melanoma (b) FGFR3 mutations in bladder cancer (c) FGFR1 expression in breast cancer [這裡若有蒲教授的data就好了!!] AUY 922 is an inhibitor […]
Novartis 石明石博士 Michael Shi 演講 Read More »